ClinicalTrials.gg
CompletedNCT03369808Updated Oct 15, 2024

A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine

A Phase 1/2 interventional study of 7.5μg H7N9 Vaccine and Phosphate Buffer Solution in H7N9 Influenza, sponsored by Shanghai Institute Of Biological Products. Completed at 1 site in China. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Shanghai Institute Of Biological Products (part of Sinopharm) · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Influenza, Human by Sinopharm — 2 open to participants now, 2 under way, none of them phase 3. Influenza, Human · Sinopharm.

Enrollment
11th of 15
360 · median 560
Started
2017
the only one that year
Phase 1/2
Only one
of the 15
Registered
3rd of 15
by date

Among the 15 studies in Influenza, Human by Sinopharm, this one is the 11th largest by enrollment, is the only one that started in 2017, is the only one in phase 1/2, and was the 3rd registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 15 studies in Influenza, Human by Sinopharm are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Influenza, Human by Sinopharm, or all of them as a file.
02

Study summary

The aim of this study is to investigate the immunogenicity and safety of the inactivated whole-virion vaccine for teenagers and adults.

The investigators will test the vaccine in participants aged 12-60 years, for a randomized, blind, placebo-controlled, age-stratified clinical study. The investigators designed three dosage groups: 7.5 μg,15 μg and 30 μg of hemagglutinin antigen. According to the age of the subjects, Each group was divided into different age subgroups. Phosphate buffer solution and Aluminum hydroxide adjuvant as placebo controls were both set up in the subgroups.Participants will receive 2 doses of vaccine at 21-day intervals.Safety up to 6 months and changes in hemagglutinin inhibition (HI) titers at 21 days after each vaccination were determined.

03

Conditions studied

  • H7N9 Influenza

Browse trials for

Keywords

  • H7N9
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over the age of 12 years,healthy population
  • Subjects/ (and the guardian) , voluntarily participated and signed the informed consent form, with the ability to use thermometers, scales and to fill in diary cards as required
  • To comply with the requirements of clinical trial program, receive blood test before and after immunization and cooperate with follow-up

Exclusion criteria

Exclusion Criteria:

  • A history of influenza A (H7N9) virus infection or suspected infection Abnormal blood routine, blood biochemistry and urine routine examination indexes
  • Allergy to any component in the vaccine (allergy history of any previous vaccination), especially for egg allergy
  • History of asthma, history of thyroid resection, vascular nerve edema, diabetes mellitus, hypertension can not be controlled by medicine, liver and kidney diseases or malignant tumor history
  • Suffered from any serious illness, such as cancer, disease, progressive atherosclerotic disease or complications of diabetes, , need oxygen therapy for acute or progressive liver or kidney disease, congestive heart-failure etc.
  • History of signs disease or symptoms of neurological symptoms
  • Suffering from severe chronic diseases (such as Down's syndrome, diabetes, sicklemia or neurological disorders, Green's Barre syndrome)
  • Acute attacks of various acute or chronic diseases in the past 7 days
  • Known or suspected of respiratory disease, acute infection or chronic disease active period, infection, cardiovascular disease, severe hypertension, malignant tumor during treatment, skin diseases
  • Congenital malformations or developmental disorders, genetic defects, severe malnutrition etc
  • No spleen, functional absence of spleen, and splenectomy or splenectomy without any condition
  • Autoimmune diseases or immunodeficiency have been treated with agents in the past 6 months
  • History of epilepsy, convulsions, or a family history of psychosis
  • Abnormal coagulation function (such as coagulation factor deficiency, coagulation disorders, abnormalities), or obvious bruising or coagulopathy
  • The blood products were received within 3 months prior to the acceptance of the vaccine
  • Received a within 14 days prior to receiving the vaccine, or received a subunit or inactivated vaccine within 7 days
  • Fever within 3 days prior to vaccination, axillary temperature ≥38 ℃
  • Being febrile When inoculating vaccine, axillary temperature >37.0 ℃
  • Women are pregnant or in the near future planned pregnancy or pregnancy test positive
  • Participants in another clinical trial
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
360 participants (actual)

Study arms

  • Experimental
    7.5μg H7N9 Vaccine

    Participants will receive 2 doses of 7.5μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.

    Biological: 7.5μg H7N9 Vaccine

  • Experimental
    15μg H7N9 Vaccine

    Participants will receive 2 doses of 15μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.

    Biological: 15μg H7N9 Vaccine

  • Experimental
    30μg H7N9 vaccine

    Participants will receive 2 doses of 30μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.

    Biological: 30μg H7N9 Vaccine

  • Placebo comparator
    Aluminum hydroxide adjuvant

    Participants will receive 2 doses of aluminum hydroxide adjuvant at 21-day intervals.

    Biological: Aluminum Hydroxide Adjuvant

  • Placebo comparator
    Phosphate buffer solution

    Participants will receive 2 doses of phosphate buffer solution at 21-day intervals.

    Biological: Phosphate Buffer Solution

Interventions

  • Biological7.5μg H7N9 Vaccine

    The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs,mixed with aluminum hydroxide adjuvant.

  • BiologicalPhosphate Buffer Solution

    0.5ml phosphate buffer solution

  • BiologicalAluminum Hydroxide Adjuvant

    0.5ml aluminum hydroxide adjuvant

  • Biological15μg H7N9 Vaccine

    The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs,mixed with aluminum hydroxide adjuvant.

  • Biological30μg H7N9 Vaccine

    The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs,mixed with aluminum hydroxide adjuvant.

06

What researchers measure

Primary outcomes

  1. Reactogenicity Events

    * For each group the incidence rate of subjects with solicited AE(s) with 95% confidence interval * For each group the incidence rate of subjects with solicited SAE(s) with 95% confidence interval

    Time frame: Continuous observation for 30 days after two inoculations

Secondary outcomes

  1. Number of participants that presented seroconversion post injection

    * Seroconvertion is defined as: prevaccination Hemagglutination-inhibition test (HI) antibody titer ≤1:10 and postvaccination HI antibody titer ≥1:40, or prevaccination HI antibody titer ≥1:10 and a postvaccination increase by a factor of four or more. * Participants will be collected blood post first study injection, when blood samples will be taken for HI testing.

    Time frame: 21 days after two inoculations

  2. Number of participants that presented seroprotection post injection

    * Seroprotection is defined as postvaccination Hemagglutination-inhibition test (HI) antibody titer ≥ 1:40. * Participants will be collected blood post first study injection, when blood samples will be taken for HI testing.

    Time frame: 21 days after two inoculations

  3. Geometric mean of Hemagglutination-inhibition titre post first study injection

    * Geometric mean of Hemagglutination-inhibition test titre will be calculated for the different groups of participants post first study injection. * Participants will be collected blood post first study injection, when blood samples will be taken for HI testing.

    Time frame: 21 days after two inoculations

07

Study locations

1 site
  • Suiping Center for Disease Control and Prevention
    Zhumadian, Henan 463100, China
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Aug 2018, 8 months.

Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 8 months is below that.

Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2017
First posted
Dec 12, 2017
StartActual
Dec 29, 2017
Primary completionActual
Aug 29, 2018
CompletionActual
Nov 15, 2019
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03369808
Collaborators
Henan Center for Disease Control and Prevention
Responsible party
Sponsor
First posted
Dec 12, 2017
Start date
Dec 29, 2017
Primary completion
Aug 29, 2018
Completion
Nov 15, 2019
Last update
Oct 15, 2024

Study contacts

Ze Chen, PhD
principal investigator · Shanghai Institute Of Biological Products

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion